[{"orgOrder":0,"company":"Option Care Health","sponsor":"NS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Viltolarsen","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Option Care Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Option Care Health \/ NS Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Option Care Health \/ NS Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Option Care Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Option Care Health has been selected to participate in the limited distribution network of VILTEPSO™ (viltolarsen) for patients with Duchenne Muscular Dystrophy (“DMD”) who are amenable to exon 53 skipping therapy.

                          Brand Name : Viltepso

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 02, 2020

                          Lead Product(s) : Viltolarsen

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Sponsor : NS Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank